CANCER:

Esophageal Cancer

Related cancers:

‹

Esophageal Squamous Cell Carcinoma (43)

Esophageal Adenocarcinoma (24)

Esophageal Squamous Cell Carcinoma (43)

Esophageal Adenocarcinoma (24)

›

No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	nivolumab Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 2 days
No biomarker No biomarker	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Esophageal Cancer Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	XP Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	ramucirumab Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	docetaxel + irinotecan Sensitive: A2 - Guideline
HER-2 positive HER-2 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline
HER-2 overexpression HER-2 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	5-fluorouracil + irinotecan Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	irinotecan Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	CaT Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	docetaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	IP Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	capecitabine + oxaliplatin Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Esophageal Cancer Esophageal Cancer	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Esophageal Cancer Esophageal Cancer	larotrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Esophageal Cancer Esophageal Cancer	larotrectinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Esophageal Cancer Esophageal Cancer	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Esophageal Cancer Esophageal Cancer	entrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Esophageal Cancer Esophageal Cancer	entrectinib Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	FP Sensitive: A2 - Guideline
TMB-H TMB-H	Esophageal Cancer Esophageal Cancer	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	paclitaxel + capecitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	DP Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	FLOT Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	oxaliplatin Sensitive: A2 - Guideline
HER-2 Negative + PD-L1 expression HER-2 Negative + PD-L1 expression	Esophageal Cancer Esophageal Cancer	pembrolizumab Sensitive: A2 - Guideline
HER-2 Negative + PD-L1 expression HER-2 Negative + PD-L1 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	nivolumab Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	Esophageal Cancer Esophageal Cancer	XP Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	Esophageal Cancer Esophageal Cancer	FP Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	Esophageal Cancer Esophageal Cancer	capecitabine + oxaliplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	DOF Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	carboplatin + 5-fluorouracil + docetaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	TPF Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	FOLFOX Sensitive: A2 - Guideline
HER-2 overexpression HER-2 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: B - Late Trials
EGFR overexpression EGFR overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	erlotinib Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	nivolumab Sensitive: B - Late Trials
No biomarker No biomarker	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	tislelizumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	tislelizumab Sensitive: B - Late Trials
MSI-H/dMMR MSI-H/dMMR	Esophageal Cancer Esophageal Cancer	dostarlimab Resistant: C1 - Off-label
NTRK3 fusion NTRK3 fusion	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	larotrectinib Sensitive: C1 - Off-label
NTRK2 fusion NTRK2 fusion	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	larotrectinib Sensitive: C1 - Off-label
NTRK1 fusion NTRK1 fusion	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	larotrectinib Sensitive: C1 - Off-label
EGFR mutation EGFR mutation	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	afatinib Sensitive: C1 - Off-label
HER-2 overexpression HER-2 overexpression	Esophageal Cancer Esophageal Cancer	trastuzumab Sensitive: C1 - Off-label
HER-2 positive HER-2 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	trastuzumab + pertuzumab Sensitive: C1 - Off-label
HER-2 positive HER-2 positive	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	trastuzumab Sensitive: C1 - Off-label
EGFR amplification EGFR amplification	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	afatinib Sensitive: C2 – Inclusion Criteria
MYC amplification MYC amplification	Esophageal Cancer Esophageal Cancer	ibrutinib Sensitive: C2 – Inclusion Criteria
HER-2 amplification HER-2 amplification	Esophageal Cancer Esophageal Cancer	ibrutinib Sensitive: C2 – Inclusion Criteria
HER-2 amplification HER-2 amplification	Esophageal Cancer Esophageal Cancer	avelumab Sensitive: C2 – Inclusion Criteria
CLDN18.2 expression CLDN18.2 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	IMAB362 Sensitive: C2 – Inclusion Criteria
HER-2 amplification HER-2 amplification	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Esophageal Cancer Esophageal Cancer	atezolizumab + MTIG7192A Sensitive: C2 – Inclusion Criteria
NRG1 overexpression NRG1 overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	AV-203 Sensitive: C3 – Early Trials
NDRG1 overexpression NDRG1 overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	cisplatin + 5-fluorouracil Resistant: C3 – Early Trials
SGK1 overexpression SGK1 overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	cisplatin + 5-fluorouracil Resistant: C3 – Early Trials
HER-2 positive HER-2 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	paclitaxel Resistant: C3 – Early Trials
HER-2 positive HER-2 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	carboplatin Resistant: C3 – Early Trials
AFAP1-AS1 overexpression AFAP1-AS1 overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	FP Resistant: C3 – Early Trials
ARID1A mutation ARID1A mutation	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	camrelizumab Sensitive: C3 – Early Trials
TLR signature TLR signature	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	tislelizumab Sensitive: C3 – Early Trials
NDRG1-H NDRG1-H	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials
DKK1 overexpression DKK1 overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials
DKK1 overexpression DKK1 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials
DKK1 overexpression DKK1 overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	DKN-01 Sensitive: C3 – Early Trials
DKK1 overexpression DKK1 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	DKN-01 Sensitive: C3 – Early Trials
NFKB1 expression NFKB1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	rivoceranib Sensitive: C3 – Early Trials
KDR expression KDR expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	rivoceranib Sensitive: C3 – Early Trials
PD-L1 overexpression + CCL5 overexpression PD-L1 overexpression + CCL5 overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	toripalimab + surufatinib Sensitive: C3 – Early Trials
TMB-H TMB-H	Esophageal Cancer Esophageal Cancer	camrelizumab Sensitive: C3 – Early Trials
GRB7 positive GRB7 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	trastuzumab + carboplatin + paclitaxel + pertuzumab Sensitive: C3 – Early Trials
HER-2 overexpression HER-2 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	trastuzumab + pertuzumab Sensitive: C3 – Early Trials
HER-2 positive HER-2 positive	Esophageal Cancer Esophageal Cancer	durvalumab Resistant: C3 – Early Trials
ERCC1 negative ERCC1 negative	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	SOX Sensitive: C3 – Early Trials
TTN D7145H TTN D7145H	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	cisplatin Sensitive: C3 – Early Trials
MYH4 Q1210fs MYH4 Q1210fs	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	cisplatin Sensitive: C3 – Early Trials
MRE11A underexpression MRE11A underexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	cisplatin Resistant: C3 – Early Trials
UBQLN4 overexpression UBQLN4 overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	cisplatin Resistant: C3 – Early Trials

Esophageal Cancer

Associations(120)

Associations
(120)